Company Profile
Kalaris is a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. The company is focused on development of TH103, a novel, clinical stage anti-vascular endothelial growth factor (“VEGF”) drug. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered to achieve extended intraocular retention with enhanced VEGF inhibition in patients with exudative and/or neovascular retinal diseases. TH103 is currently being evaluated in an ongoing, Phase 1b/2 clinical trial for the treatment of nAMD, with plans to develop TH103 for other neovascular and exudative diseases of the retina such as Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).
Download Corporate Presentation
